Scleroderma Renal Crisis

📋 Key Information Summary

📋

Scleroderma renal crisis (SRC) is a medical emergency characterised by acute severe hypertension and rapidly progressive acute kidney injury (AKI) in patients with systemic sclerosis (SSc).
SRC occurs predominantly in diffuse cutaneous SSc (dcSSc), typically within the first 3–5 years of disease onset.
Anti-RNA polymerase III antibodies are the strongest serological risk factor (present in ~40–60% of SRC cases); anti-centromere antibodies are protective.
Corticosteroids ≥15 mg/day prednisolone equivalent increase SRC risk — use the lowest effective dose in early dcSSc.
ACE inhibitors (enalapril, ramipril) are first-line therapy and have dramatically reduced mortality from >80% to ~10–20%.
Start ACE inhibitors immediately upon clinical suspicion — do not wait for full investigation results.
Aim for a diastolic BP reduction of 10–20 mmHg within the first 24 hours and gradual normalisation over 48–72 hours.
Do not discontinue ACE inhibitors even if dialysis is required — renal recovery can occur weeks to months later.
Approximately 50–70% of patients will require dialysis acutely; ~40–55% of these will eventually discontinue dialysis with continued ACE inhibitor therapy.
Thrombotic microangiopathy (TMA) with microangiopathic haemolytic anaemia (MAHA) may occur and can mimic thrombotic thrombocytopaenic purpura (TTP).
Involvement of a rheumatologist and nephrologist is essential; consider transfer to a renal/transplant centre for severe cases.
ATSI patients may have delayed presentation due to geographic isolation — early rheumatology follow-up and GP education are critical in remote communities.

Introduction & Australian Epidemiology

Scleroderma renal crisis (SRC) is an acute, life-threatening complication of systemic sclerosis (SSc) characterised by the abrupt onset of severe hypertension, rapidly progressive acute kidney injury (AKI), and often microangiopathic haemolytic anaemia (MAHA). It is one of the most feared visceral manifestations of SSc and, prior to the introduction of ACE inhibitors, carried a mortality exceeding 80%. Even in the current era, in-hospital mortality remains approximately 10–20%, with significant long-term morbidity.

In Australia, the estimated prevalence of SSc is approximately 20–40 per 100,000 population, with SRC affecting 2–15% of patients with SSc, depending on the subset. Diffuse cutaneous SSc (dcSSc) carries the highest risk, with an estimated 10–20% of dcSSc patients developing SRC within the first 5 years of disease. The Australian Scleroderma Cohort Study and published data from tertiary centres in Melbourne, Sydney, and Perth have contributed significantly to the understanding of SRC risk factors, serological associations, and outcomes in the Australian context.

Aboriginal and Torres Strait Islander Australians appear to have a higher prevalence of autoimmune connective tissue diseases, although specific SRC incidence data in ATSI populations remain limited. Geographic barriers to specialist care in remote and very remote areas may delay recognition and initiation of life-saving ACE inhibitor therapy.

⚠️

Clinical alert: SRC can develop within hours to days. Any patient with SSc presenting with new or accelerated hypertension and rising creatinine must be assumed to have SRC until proven otherwise. Start an ACE inhibitor immediately — do not delay treatment for diagnostic workup.

Pathophysiology & Risk Factors

Pathophysiology

SRC results from a distinctive renal vascular injury. The hallmark lesion is concentric intimal proliferation (onion-skin lesion) of the interlobular and arcuate arteries, leading to luminal occlusion and reduced renal perfusion. This triggers activation of the renin–angiotensin–aldosterone system (RAAS), producing severe hypertension and further renal ischaemia, creating a vicious cycle.

Key pathological and mechanistic features include:

Intimal proliferation: Fibroblast and myofibroblast proliferation within arteriolar intima, producing a concentric "onion-skin" appearance on renal biopsy.
Microangiopathic haemolytic anaemia (MAHA): Red cell fragmentation through narrowed arterioles produces schistocytes, elevated LDH, and low haptoglobin.
RAAS activation: Renal ischaemia drives renin release, causing severe hypertension — often with disproportionately elevated diastolic pressures.
Endothelial dysfunction: Endothelin-1 upregulation and reduced nitric oxide contribute to vasospasm and vascular remodelling.
Thrombotic microangiopathy: In a subset, complement dysregulation may contribute to a TMA phenotype.

Risk Factors for SRC

Risk Factor	Association	Notes
Diffuse cutaneous SSc	Strong (highest risk subset)	~80% of SRC cases are dcSSc; risk highest in first 3–5 years
Anti-RNA polymerase III antibodies	Very strong	OR ~5–8; present in 40–60% of SRC patients
Corticosteroids ≥15 mg/day	Strong	Dose-dependent risk; use lowest possible dose in early dcSSc
New anaemia	Moderate	May indicate MAHA or renal failure
Large joint contractures	Moderate	Reflects extensive skin/tendon involvement
Rapid skin score progression	Moderate	Rising modified Rodnan skin score (mRSS) correlates with SRC risk
Myopathy / elevated CK	Moderate	Concurrent skeletal muscle involvement
Anti-centromere antibodies	Protective	Strongly associated with limited cutaneous SSc; SRC rare in ACA+ patients
Calcium channel blockers	Possible trigger	Theoretical risk of reducing renal perfusion; generally advised caution in early dcSSc

🚨

Corticosteroid warning: Systemic corticosteroids ≥15 mg/day prednisolone equivalent significantly increase SRC risk in early dcSSc. Avoid high-dose corticosteroids in this population. If corticosteroids are essential, use the lowest effective dose and monitor BP and creatinine closely.

Clinical Features & Presentation

SRC typically presents acutely in a patient with known SSc, although it may occasionally be the first manifestation of previously undiagnosed systemic sclerosis (particularly in older males). The classic presentation is:

Early / Incomplete

Pre-Crisis

New hypertension (often diastolic >100 mmHg) with modest creatinine rise; may have mild thrombocytopaenia. BP may rise from previously low baseline.

Setting: Urgent assessment — commence ACE inhibitor

Established

Classic SRC

Systolic BP >150 mmHg or diastolic >100 mmHg, rapid creatinine rise, MAHA (schistocytes, ↑LDH, ↓haptoglobin, ↓platelets), retinal changes (cotton-wool spots, haemorrhages), flash pulmonary oedema.

Setting: Hospital admission, ICU step-down

Severe

Malignant Hypertension / Dialysis-Dependent

Malignant hypertension (BP >180/120 with end-organ damage), encephalopathy, seizures, oligoanuria requiring dialysis, severe MAHA, cardiac involvement (pericardial effusion, arrhythmias).

Setting: ICU / HDU admission

Key Clinical Features

Hypertension: New or significantly accelerated; often diastolic predominant. Note: ~10% of SRC cases present as "normotensive SRC" — particularly in patients with pre-existing low baseline BP or concurrent scleroderma cardiac involvement.
AKI: Rapidly rising creatinine (often doubling within days to weeks); oliguria or anuria in severe cases.
MAHA: Microangiopathic haemolytic anaemia with schistocytes on blood film, elevated LDH, undetectable haptoglobin, and thrombocytopaenia.
Hypertensive retinopathy: Fundoscopy may reveal cotton-wool spots, flame haemorrhages, papilloedema.
Pulmonary oedema: May be cardiogenic (hypertensive) or non-cardiogenic (capillary leak); can develop rapidly.
Encephalopathy: Headache, confusion, seizures, visual disturbance in severe cases.
Microscopic haematuria and proteinuria: Usually mild; nephrotic-range proteinuria is uncommon and suggests an alternative or concurrent diagnosis.

⚠️

Normotensive SRC: Approximately 10% of SRC cases present without overt hypertension. Maintain a high index of suspicion for SRC in any SSc patient with unexplained AKI, new anaemia, or thrombocytopaenia. A rising creatinine above the patient's baseline in early dcSSc warrants urgent evaluation.

Investigations & Diagnosis

SRC is primarily a clinical diagnosis based on new-onset hypertension and AKI in a patient with SSc. Investigations support the diagnosis and exclude mimics. Do not delay ACE inhibitor therapy while awaiting results.

Essential Investigations

ESSENTIAL

Serum creatinine, eGFR, electrolytes

Baseline and serial monitoring; expect rapidly rising creatinine. Hyperkalaemia may be present due to AKI and RAAS activation. MBS item 66509 (eGFR).

ESSENTIAL

Full blood count (FBC) with blood film

Look for schistocytes (MAHA), thrombocytopaenia, anaemia. MBS item 65070.

ESSENTIAL

Peripheral blood film

Schistocytes confirm MAHA; distinguishes SRC from other causes of AKI.

ESSENTIAL

LDH, haptoglobin, reticulocyte count

Elevated LDH and low haptoglobin support haemolysis. MBS item 65080.

ESSENTIAL

Renin, aldosterone levels

Elevated renin confirms RAAS activation. Collect before starting ACE inhibitor if feasible — but do NOT delay treatment.

ESSENTIAL

Urinalysis, urine microscopy, urine protein:creatinine ratio

Mild proteinuria and microscopic haematuria expected. Heavy proteinuria (>3 g/day) suggests an alternative diagnosis. MBS item 65080.

AVAILABLE

ADAMTS13 activity

To exclude TTP if MAHA is prominent; ADAMTS13 is typically normal or mildly reduced in SRC. Result may take days — do not delay treatment.

AVAILABLE

SSc autoantibody panel (ANA, anti-RNA Pol III, anti-Scl-70, ACA)

Anti-RNA Pol III positive status strongly supports SRC; result available in 5–10 days at reference labs (e.g., St Vincent's Melbourne, Westmead).

AVAILABLE

Fundoscopy

Hypertensive retinopathy findings support the diagnosis and severity assessment.

REFERRAL

Renal biopsy

Not always required for diagnosis but may be considered if atypical features, diagnostic uncertainty, or heavy proteinuria. Shows intimal proliferation, fibrinoid necrosis, ischaemic glomerular changes. Perform only if safe (watch BP, platelets).

AVAILABLE

ECG, troponin, echocardiography

Assess for hypertensive cardiomyopathy, pericardial effusion, LVH. Standard hospital-based investigations.

Diagnostic Criteria

There is no single pathognomonic test. SRC is diagnosed when a patient with SSc (typically early dcSSc) develops:

New or accelerated hypertension (usually BP >150/90 mmHg, or >30/20 mmHg above baseline)
AKI (creatinine rise >50% from baseline or >1.5× baseline)
± features of MAHA (schistocytes, ↑LDH, ↓haptoglobin, ↓platelets)
± elevated plasma renin

ℹ️

DDx — exclude: Thrombotic thrombocytopaenic purpura (TTP), haemolytic uraemic syndrome (HUS), drug-induced AKI (NSAIDs, calcineurin inhibitors), hypertensive emergency from other causes, renal artery stenosis, cholesterol emboli syndrome, APS nephropathy.

Management

SRC management centres on aggressive RAAS blockade with ACE inhibitors, supportive care, dialysis if required, and multidisciplinary involvement (rheumatology, nephrology, ICU). Treatment should never be delayed.

First-Line: ACE Inhibitors

ACE inhibitors are the cornerstone of SRC treatment and the single most important intervention. They block the pathological RAAS activation driving SRC. Initiate immediately at the first clinical suspicion.

💊

Enalapril

Renitec® · Alphapharm · ACE inhibitor — first-line

Adult dose Start 2.5–5 mg PO/NG BD; titrate rapidly to effect (up to 40 mg/day in divided doses). In severe cases, IV enalaprilat 1.25 mg IV q6h may be used initially.

Paediatric dose 0.1 mg/kg/day in 1–2 divided doses; max 0.5 mg/kg/day. Paediatric SRC is rare.

Route Oral (preferred) or IV (enalaprilat)

Renal adjustment Initiate cautiously; reduce dose if eGFR <30. Monitor K⁺ closely. Continue even on dialysis.

PBS status ✔ PBS General Benefit

💊

Captopril

Capoten® · Generic · ACE inhibitor — alternative

Adult dose Start 6.25–12.5 mg PO TDS; titrate to 25–50 mg TDS. Short half-life allows rapid dose titration.

Renal adjustment Use with caution in severe AKI; monitor K⁺ and creatinine closely.

PBS status ✔ PBS General Benefit

💊

Ramipril

Tritace® · Generic · ACE inhibitor — alternative

Adult dose Start 1.25–2.5 mg PO BD; titrate to 10 mg/day in divided doses.

Renal adjustment Max 5 mg/day if eGFR <30. Monitor K⁺ closely.

PBS status ✔ PBS General Benefit

Blood Pressure Targets & Monitoring

1

First 24 hours

Aim to reduce diastolic BP by 10–20 mmHg. Avoid aggressive lowering — renal perfusion depends on adequate pressure. Monitor BP every 1–2 hours initially. Target BP: individualised; generally avoid dropping systolic below 110–120 mmHg acutely.

2

48–72 hours

Gradual normalisation toward target <130/80 mmHg. Titrate ACE inhibitor upward every 12–24 hours based on BP and creatinine response. Add second agent if needed (see below).

3

Ongoing

Maintain BP <130/80 mmHg. Serial creatinine monitoring (daily initially, then 2–3×/week). Monitor FBC, LDH, haptoglobin for MAHA resolution. Monitor K⁺.

Second-Line & Adjunctive Agents

If BP is not adequately controlled with maximal ACE inhibitor doses, add:

💊

Amlodipine

Norvasc® · Generic · Dihydropyridine CCB

Adult dose 5–10 mg PO daily. Preferred CCB in SRC (avoid non-dihydropyridines which may worsen Raynaud's).

PBS status ✔ PBS General Benefit

💊

Losartan

Cozaar® · Generic · ARB — if ACEi intolerant

Adult dose 50–100 mg PO daily. Use only if ACE inhibitor intolerant (e.g., intractable cough). Less evidence in SRC than ACE inhibitors.

PBS status ✔ PBS General Benefit

💊

IV Labetalol

Trandate® · α/β-blocker — hypertensive emergency

Adult dose 20 mg IV bolus over 2 min; repeat 20–80 mg every 10–20 min (max 300 mg). Infusion: 1–2 mg/min titrated to BP.

PBS status 🏥 Hospital only

💊

IV Sodium Nitroprusside

Nipride® · Vasodilator — refractory hypertensive emergency

Adult dose 0.3–0.5 mcg/kg/min IV infusion; titrate to max 8–10 mcg/kg/min. ICU monitoring required. Thiocyanate toxicity risk with prolonged use (>72 h) or renal failure.

PBS status 🏥 Hospital only

⚠️

ARB vs ACEi: ACE inhibitors are superior to ARBs in SRC. ARBs should only be used if there is true ACE inhibitor intolerance (angioedema, intractable cough). Do not use ACEi + ARB combination — this increases adverse events without proven benefit.

Agents to Avoid

Calcium channel blockers (non-dihydropyridine): Verapamil and diltiazem may impair renal perfusion and worsen Raynaud's. Dihydropyridines (amlodipine) are acceptable as add-on therapy.
Beta-blockers: Generally avoided in SSc due to worsening of Raynaud's phenomenon; use only if compelling cardiac indication.
NSAIDs: Contraindicated — nephrotoxic, worsen renal perfusion, may precipitate SRC.
High-dose corticosteroids: ≥15 mg/day prednisolone equivalent is an independent risk factor for SRC.

Dialysis

Approximately 50–70% of SRC patients will require dialysis at some point during the acute illness. Indications for dialysis are the same as for other causes of AKI:

Refractory hyperkalaemia despite medical management
Severe metabolic acidosis (pH <7.1)
Fluid overload with pulmonary oedema unresponsive to diuretics
Uraemic symptoms (encephalopathy, pericarditis)
Oligoanuria (<200 mL/24h) with progressive uraemia

Key principle: Continue ACE inhibitors even when dialysis is commenced. Renal recovery may occur weeks to months after SRC onset, particularly with ongoing RAAS blockade. Studies show that 40–55% of patients initially requiring dialysis eventually become dialysis-independent, especially if ACE inhibitor therapy is maintained.

✅

Do not stop ACE inhibitors on dialysis: Ongoing ACE inhibitor therapy is independently associated with dialysis discontinuation and renal recovery. Continue enalapril or equivalent throughout dialysis unless symptomatic hypotension or hyperkalaemia is intractable.

Emerging & Adjunctive Therapies

Bosentan (endothelin receptor antagonist): Case reports and small series suggest potential benefit in refractory SRC. Not PBS-listed for this indication; requires specialist initiation and authority application.
Eculizumab (complement C5 inhibitor): Considered if a complement-mediated TMA phenotype is suspected. Highly expensive; requires Haematology/Renal specialist input.
Plasma exchange: May be considered if TTP cannot be excluded (while awaiting ADAMTS13 results) or in severe TMA without response to ACE inhibitors. Generally limited role in SRC itself.
Prostacyclin analogues (iloprost IV): May improve renal perfusion and digital ulceration; specialist use only.

Supportive Care

Fluid and electrolyte management — monitor K⁺ closely (RAAS blockade + AKI → hyperkalaemia risk)
ECG monitoring for arrhythmias in severe cases
Manage pulmonary oedema (diuretics, NIV, or dialysis as indicated)
Nutritional support — consider dietitian input
Psychological support — SSc with SRC carries high morbidity and mortality; patients and families require ongoing counselling

Special Populations

🤰 Pregnancy

ACE inhibitors are teratogenic (Category D)

Contraindicated in pregnancy. In SRC during pregnancy, use labetalol, hydralazine, or methyldopa for BP control. Involve obstetric medicine and nephrology. Risk of pre-eclampsia overlap — distinguish from SRC carefully. Delivery may be required if maternal condition deteriorates.

👶 Paediatrics

Paediatric SRC is extremely rare

Almost exclusively described in adults. If encountered in a child with juvenile SSc, management principles are similar (ACE inhibitor first-line). Paediatric nephrology should be involved. Dose enalapril 0.1 mg/kg/day in 1–2 divided doses (max 0.5 mg/kg/day).

👴 Elderly

Caution with aggressive BP lowering

Elderly patients are more susceptible to hypotension-related complications (falls, syncope, stroke). Titrate ACE inhibitors more cautiously. Baseline renal impairment is more common — start at lower doses and monitor closely. Assess for concurrent cardiac disease.

🩺 Pre-existing CKD

ACE inhibitor dose adjustment required

Patients with pre-existing CKD are at higher risk of severe SRC. Start ACE inhibitors at lower doses. Monitor K⁺ and creatinine every 6–12 hours initially. Dialysis may be required sooner. Renal replacement therapy planning should begin early.

🫁 Hepatic Impairment

SSc liver involvement uncommon

If hepatic impairment is present, enalapril and captopril are preferred as they do not require hepatic activation (unlike ramipril which requires hepatic conversion to ramiprilat). Monitor LFTs. Consider autoimmune hepatitis overlap.

🛡️ Immunocompromised

Immunosuppression may mask infection

Patients on immunosuppressants (mycophenolate, methotrexate, cyclophosphamide) for SSc may present with sepsis mimicking SRC. Always exclude sepsis as a contributor to AKI. Avoid high-dose corticosteroids if possible (SRC risk). Immunosuppressant dose adjustments may be needed in AKI.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a higher burden of autoimmune rheumatic diseases and chronic kidney disease compared to non-Indigenous Australians. While specific data on SRC in ATSI populations are limited, several factors contribute to disparities in outcomes:

Geographic isolation

Many ATSI patients live in remote and very remote communities with limited access to rheumatology, nephrology, and ICU services. SRC requires rapid specialist assessment and initiation of ACE inhibitors — delays associated with long-distance transfer may worsen outcomes. Telehealth rheumatology and nephrology consultations should be maximised.

Higher background CKD prevalence

ATSI Australians have 2–3× the rate of CKD compared to non-Indigenous Australians. Pre-existing CKD increases the severity of SRC and the likelihood of dialysis dependence. Earlier nephrology referral is warranted.

Delayed diagnosis

SSc may be underdiagnosed in ATSI communities. GPs in remote areas should maintain a high index of suspicion for SRC in any ATSI patient with new hypertension and AKI, particularly if there is skin thickening, Raynaud's, or digital ulceration.

PBS access

ACE inhibitors (enalapril, captopril, ramipril) are available as PBS General Benefits, ensuring equitable access. Patients in remote areas may face supply-chain issues — ensure adequate medication supply and backup plans via remote area pharmacies or RFDS.

Cultural safety

Engage Aboriginal Health Workers (AHWs) and Aboriginal Community Controlled Health Organisations (ACCHOs) in SRC education, monitoring, and follow-up. Ensure culturally safe communication regarding the seriousness of SRC and the need for lifelong ACE inhibitor therapy.

Dialysis access

ATSI patients requiring dialysis may need to relocate to regional or metropolitan centres. Support patient-centred dialysis planning, including satellite dialysis and supported return to community. The RFDS is critical for emergency transfer in remote areas.

📚 References

1. Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal outcomes in systemic sclerosis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2023;62(3):1023–1034.
2. Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford). 2012;51(3):460–467.
3. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485–494.
4. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613–1619.
5. Hissaria P, Lester S, Hakendorf P, et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J. 2011;41(5):381–390.
6. Dobrota R, Mihai C, Distler O. Renal involvement in systemic sclerosis: an update on scleroderma renal crisis. Rheumatology (Oxford). 2022;61(3):934–944.
7. Mecoli CA, Shah AA, Boin F, Wigley FM. The management of scleroderma renal crisis. Curr Opin Rheumatol. 2021;33(6):514–520.
8. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease in Aboriginal and Torres Strait Islander people. Cat. no. PHE 261. Canberra: AIHW; 2023.
9. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011;13(6):R211.
10. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67(1):110–116.
11. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339.
12. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis — results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum. 2018;48(3):466–470.